19.13
+0.26%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Amoy Diagnostics Co
Its shares trade on Shenzhen under the ticker 300685.SZ. It has been listed since 2 August 2017. In the fiscal year to 31 December 2025, it reported revenue of CN¥1.20bn and net income of CN¥357.9m. At that date it held total assets of CN¥2.35bn and shareholders' equity of CN¥2.06bn.
Amoy Diagnostics Co., Ltd. engages in the research, development, production, and sale of tumor precision molecular diagnostic products. The company is headquartered in Xiamen, Fujian. The company went IPO on 2017-08-02. The firm provides testing reagents and testing services for tumor diagnosis. The Company’s testing reagent products include ADx-ARMS product line for tumor tissue specimen detection, Super-ARMS product line for liquid biopsy, the NGS product line and the FISH product line. The products are used for the detection of non-small cell lung cancer, colorectal cancer, thyroid cancer, melanoma and other malignant tumors. The firm also provides data software to capture and analyze gene sequencing data. The firm provides testing services through its own medical testing institutions, including lung cancer testing, colorectal cancer testing and breast cancer testing.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 2 Aug 2017
- Employees
- 1,101
- Website
- amoydx.com ↗
Leadership
Pay as last reported
- Mr. Limou ZhengChairman of the Board, since 2008CN¥966,300
- Ms. Ying ChenChief Financial Officer, Secretary of the BoardCN¥821,600
- Mr. Jiemin LuoGeneral Manager, DirectorCN¥938,900
- Mr. Li RuanSenior Deputy General Manager, DirectorCN¥755,300
- Mr. Frank ZhengSenior Deputy General Manager, Director, since 2021CN¥774,300
- Mr. Zhengwei DongDeputy General Manager
- Ms. Fei LuoDeputy General Manager, Chief Sales Officer, since 2024CN¥1.0m
- Mr. Hongyu WangDeputy General Manager
- Mr. Shuang YangDeputy General Manager
- Mr. Huibin ZhengDeputy General Manager, since 2011CN¥669,900
- Mr. Guanshan ZhuDeputy General Manager, since 2014CN¥845,600
- Mr. Zhe ShenIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Amoy Diagnostics employs 1,101 full-time employees in Xiamen for tumor precision diagnostics.
- ADx-ARMS and Super-ARMS product lines support tumor tissue and liquid biopsy detection.
- NGS and FISH product lines enable comprehensive gene sequencing for cancer detection.
Weaknesses
- Amoy Diagnostics has no presence in the Financials sector or Consumer Discretionary segment.
- The company lacks products for non-cancerous tumor detection in its current portfolio.
- Amoy Diagnostics does not offer services for pediatric cancer testing as of 2023.
Opportunities
- Expanding NGS product line to include pediatric cancer detection services.
- Increasing market share in China's Health Care sector with new reagents.
- Growing demand for liquid biopsy solutions in the Biotechnology industry.
Threats
- Competition from other Biotechnology firms in China's Health Care market.
- Regulatory changes affecting tumor diagnostic product approvals.
- Economic downturns impacting healthcare spending in China.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.